Annotation Detail

Information
Associated Genes
KRAS
Associated Variants
KRAS p.Gly13Asp (p.G13D) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000685328.1, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 )
KRAS p.Gly13Asp (p.G13D) ( ENST00000556131.2, ENST00000557334.6, ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 )
Associated Disease
colorectal cancer
Source Database
CIViC Evidence
Description
In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G13D was the only variant noted in the primary rectal tumor of one patient who experienced disease progression following treatment (Patient 45; Supplemental Table 1). This is response is consistent with observations made of the larger cohort, where patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant. However, two other patients (37 and 47; Table S1) had G13D as their only noted variant, but experienced partial response.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/6322
Gene URL
https://civic.genome.wustl.edu/links/genes/30
Variant URL
https://civic.genome.wustl.edu/links/variants/81
Rating
2
Evidence Type
Predictive
Disease
Colorectal Cancer
Evidence Direction
Supports
Drug
Panitumumab,Cetuximab
Evidence Level
C
Clinical Significance
Resistance
Pubmed
19223544
Drugs
Drug NameSensitivitySupported
CetuximabResitance or Non-Reponsetrue
PanitumumabResitance or Non-Reponsetrue